Ferronova's Significant Milestone in Cancer Treatment
Australian company Ferronova has reached an impressive milestone by announcing the completion of patient enrolment for its innovative trial focused on the commercialization of FerroTrace. This advanced nanoparticle image-guided surgery tool is specifically designed to assist surgeons in effectively addressing hard-to-treat cancers.
What is FerroTrace?
The FerroTrace technology aims to enhance surgical precision by helping surgeons identify lymph nodes that have been affected by cancerous cells. With the ability to pinpoint these nodes, the technology reduces the risk of post-surgical recurrence of cancer, significantly benefiting patients undergoing surgery.
Trial Details
This pioneering trial is notable as it involves tracer injections to map lymphatic drainage pathways before any chemotherapy or radiotherapy treatments are administered. Such a method is unprecedented and holds great promise for improving treatment outcomes.
Key Highlights of the Trial
The trial has successfully enrolled 62 adult patients with gastric and oesophageal cancers at five hospital sites in Australia, which surpasses the initial projections for participant numbers.
- The anticipated evaluations and results from this trial are expected to be made available by mid-2026.
- Prior to this, several smaller first-in-human studies were conducted from 2020 to 2024 to support the technology's development.
- FerroTrace is addressing a significant need in surgical guidance for challenging cancers that rank among the top five deadliest types worldwide.
- Over 1.8 million people globally are impacted by stomach and oesophageal cancers annually, with recurrence rates reaching up to 60% post-surgery. In Australia, the three-year survival rate for oesophageal cancer stands at just 27%.
How FerroTrace Works
FerroTrace consists of super-paramagnetic iron oxide nanoparticles that bind to cells in lymph nodes. This innovative technology promises to enhance the accuracy of surgical procedures, thereby assisting surgeons in successfully locating and removing affected lymph nodes that may often be overlooked in traditional methods.
CEO's Enthusiasm and Future Outlook
Stewart Bartlett, the Chief Executive Officer of Ferronova, expressed his enthusiasm regarding the trial's enrolment completion. He acknowledged the remarkable efforts of investigators from notable institutions such as Royal Adelaide, Queen Elizabeth, Flinders, Austin Hospital, and Peter MacCallum Cancer Centre in recruiting patients within a short timeframe.
"We are eager to collaborate with these institutions to complete the final follow-up visits and analyze the trial data. Our ultimate goal is to enhance surgeons' diagnostic accuracy, enabling minimally invasive surgeries and ensuring that all cancer-affected lymph nodes are effectively identified and removed. This step is crucial in validating our technology as we progress toward making it commercially available,” Bartlett stated.
Introducing a Valuable Advisory Resource
In parallel with the trial's progress, Ferronova has appointed Ms. Aki Smith, a dedicated patient advocate and founder of the US-based charity 'Hope for Stomach Cancer', to its scientific advisory board. Ms. Smith’s firsthand experience with stomach cancer brings invaluable insights that will shape future trial designs and innovations.
Mr. Bartlett welcomed Ms. Smith, emphasizing the importance of her role and contributions: "The involvement of patient advocates like Ms. Smith is integral to our mission at Ferronova. We are committed to developing effective solutions for those affected by these aggressive cancers and believe that incorporating patient perspectives will enhance the treatment development process, including those involving our technology.”
About Ferronova
Ferronova, a pivotal player in medical technology, is headquartered in Adelaide, South Australia. The company's mission is to transform treatment options for patients with complex cancers in early stages, ultimately aiming to improve survival rates through its unique surgical oncology tracer system.
The company has strong backing from various stakeholders, including Renew Pharmaceuticals Limited, Uniseed/UniSuper, the South Australian Venture Capital Fund, and several respected universities and venture capital partners. Additional funding support has been provided by state and federal government initiatives since 2016.
Frequently Asked Questions
What is FerroTrace?
FerroTrace is a novel nanoparticle image-guided surgery solution designed to assist surgeons in reliably identifying cancer-affected lymph nodes.
How many patients were enrolled in the trial?
A total of 62 patients with gastric and oesophageal cancers were enrolled in the trial across five hospital sites in Australia.
What is the expected timeline for trial results?
Evaluations and results from the trial are anticipated to be available by mid-2026.
Who is the CEO of Ferronova?
Stewart Bartlett is the Chief Executive Officer of Ferronova.
What role does Ms. Aki Smith play in the company?
Ms. Aki Smith has been appointed to the scientific advisory board and will contribute her insights based on her experience as a patient advocate.
